Floatz logo

BUSULFANUM

Graft Versus Host Disease

City of Hope Medical CenterSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Graft Versus Host Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 4BBB
Thiotepa
Memorial Sloan Kettering Cancer Center
Phase 4BBB
Nivestim
City of Hope Medical Center
Phase 4BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BB
Ruxolitinib
Jonathan Brammer
Phase 4BB

View all 49 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →
Fanconi anemiaActive
BBB
Indicative · Phase 2/3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →